Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.
99mTc-PYP, 99mTc-pyrophosphate
AF, atrial fibrillation
ATTR-CM, transthyretin amyloid cardiomyopathy
CMR, cardiac magnetic resonance
H/CL, heart to contralateral
HF, heart failure
LGE, late gadolinium enhancement
MCF, myocardial contraction fraction
NT-proBNP, N-terminal pro-B-type natriuretic peptide
NYHA, New York Heart Association
SVI, stroke volume index
TTR, transthyretin
V122I, valine-122-isoleucine
amyloidosis
biomarkers
cardiac magnetic resonance
cardiomyopathy
eGFR, estimated glomerular filtration rate
echocardiography
nuclear imaging
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
16
09
2019
revised:
30
10
2019
accepted:
04
11
2019
entrez:
16
8
2021
pubmed:
17
12
2019
medline:
17
12
2019
Statut:
epublish
Résumé
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
Identifiants
pubmed: 34396189
doi: 10.1016/j.jaccao.2019.11.006
pii: S2666-0873(19)30091-2
pmc: PMC8352120
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
273-279Informations de copyright
© 2019 The Authors.
Références
J Am Coll Cardiol. 2019 Feb 12;73(5):589-597
pubmed: 30732713
Eur Heart J. 2017 Oct 7;38(38):2879-2887
pubmed: 29019612
Circ Cardiovasc Imaging. 2016 Aug;9(8):
pubmed: 27511979
Amyloid. 2015;22(4):210-20
pubmed: 26465835
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):234-242
pubmed: 28917675
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
J Am Heart Assoc. 2013 Apr 22;2(2):e000098
pubmed: 23608605
J Am Coll Cardiol. 2002 Jul 17;40(2):325-9
pubmed: 12106939
Curr Treat Options Cardiovasc Med. 2019 Jul 15;21(8):40
pubmed: 31309347
Genet Med. 2017 Jul;19(7):733-742
pubmed: 28102864
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
Circulation. 2009 Sep 29;120(13):1203-12
pubmed: 19752327
Circ Cardiovasc Imaging. 2018 May;11(5):e006588
pubmed: 29752392
J Cardiovasc Magn Reson. 2017 Dec 7;19(1):98
pubmed: 29212513
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
J Am Coll Cardiol. 2017 Jul 25;70(4):466-477
pubmed: 28728692
JACC Cardiovasc Imaging. 2016 Feb;9(2):126-38
pubmed: 26777222
Circulation. 2015 Oct 20;132(16):1570-9
pubmed: 26362631
ESC Heart Fail. 2018 Oct;5(5):772-779
pubmed: 29916559
Amyloid. 2015;22(3):147-55
pubmed: 25997105
JAMA Cardiol. 2016 Nov 1;1(8):880-889
pubmed: 27557400
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
J Card Fail. 2018 Aug;24(8):504-511
pubmed: 30010028